Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection.
about
Inhibitory antibodies targeting emerging viruses: advancements and mechanismsConverting monoclonal antibody-based immunotherapies from passive to active: bringing immune complexes into playA review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?Monoclonal antibodies for the treatment of Ebola virus disease.Structure of the Ebola virus glycoprotein spike within the virion envelope at 11 Å resolution.A "Trojan horse" bispecific-antibody strategy for broad protection against ebolavirusesHuman antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies.Chimeric Filoviruses for Identification and Characterization of Monoclonal AntibodiesIntegrated sequence and immunology filovirus database at Los AlamosPotent neutralizing monoclonal antibodies against Ebola virus infectionAntibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding SiteIsolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreakStructures of Ebola virus GP and sGP in complex with therapeutic antibodies.Ferrets Infected with Bundibugyo Virus or Ebola Virus Recapitulate Important Aspects of Human Filovirus Disease.Successful post-exposure prophylaxis of Ebola infected non-human primates using Ebola glycoprotein-specific equine IgG.Clinical Evaluation of Ebola Virus Disease Therapeutics.Rare, high-affinity anti-pathogen antibodies from human repertoires, discovered using microfluidics and molecular genomics.Novel Cross-Reactive Monoclonal Antibodies against Ebolavirus Glycoproteins Show Protection in a Murine Challenge Model.Toremifene interacts with and destabilizes the Ebola virus glycoproteinMarburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses.Strategies to induce broadly protective antibody responses to viral glycoproteins.Chemically Modified Human Serum Albumin Potently Blocks Entry of Ebola Pseudoviruses and Viruslike Particles.Host Factors Involved in Ebola Virus Replication.Considerations for use of Ebola vaccine during an emergency response.Principles of Broad and Potent Antiviral Human Antibodies: Insights for Vaccine Design.Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability.Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses.Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebolavirus.A Sensitive in Vitro High-Throughput Screen To Identify Pan-filoviral Replication Inhibitors Targeting the VP35-NP Interface.[Field assessment of the new rapid diagnostic test Ebola eZYSCREEN®].Filovirus Structural Biology: The Molecules in the Machine.The bulky and the sweet: How neutralizing antibodies and glycan receptors compete for virus binding.In Vivo Production of Monoclonal Antibodies by Gene Transfer via Electroporation Protects against Lethal Influenza and Ebola Infections.Passive immunotherapy of viral infections: 'super-antibodies' enter the fray.Intramuscular Adeno-Associated Virus-Mediated Expression of Monoclonal Antibodies Provides 100% Protection Against Ebola Virus Infection in Mice.Design and evaluation of bi- and trispecific antibodies targeting multiple filovirus glycoproteins.Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region.Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola VirusThe structural basis for filovirus neutralization by monoclonal antibodiesSystematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection
P2860
Q24289645-F561130D-BD08-4EFC-9964-494F33720A36Q27468870-D488E69F-AFFA-4400-A8DE-73D350D3008EQ29994671-CB0A7DBF-AE1B-4F9C-A35C-22713AA2D6F8Q30245073-0DB0B013-A088-45C8-9585-ECC619035CD8Q33551748-B36210BB-4E69-4862-BF2D-709C3CFF1C27Q34539842-57199D91-05D3-46FF-9407-E958FA5DF7D3Q36178499-2E4A5662-E8DA-4489-9723-77E986087A2CQ36736403-3F909542-F3E9-4A7D-B4BD-B156DA3112FCQ36821995-CC07D27E-6ECB-4A5F-A8AA-311BA90542AFQ36903111-A379F16F-4161-4BE1-9AD5-01398A0B2659Q36913606-9DF2C48F-24D5-412B-8993-3C5C8CB202A0Q36988908-177A5E11-D7F2-4703-B015-0EEFB085FC02Q37213985-AA340168-6832-4C10-AB95-2B9AD9EB384BQ37300391-9E01447B-2E1B-4036-8216-6316553B8B30Q37623149-9BBE97E5-E786-449E-81CC-E4D49BC0ACB8Q38617605-106DA5E9-56C0-42F6-89DA-3041F28899D3Q38636738-7835E8C9-0BC7-41F3-AEAF-5F49BE1C1E2DQ38673543-A5816619-E892-4883-9969-E478DBC65D0DQ38760720-09B6A275-E7D4-4530-BA0C-8CAAE3F91B71Q38848150-39580C47-C9CB-49DD-8664-20CF5EB760B3Q39170802-674696C7-C0A2-47E9-8BED-714F95655324Q39175134-87699DD9-37AA-47A8-A359-ACC8FC1E8550Q39436358-87777780-CE78-45C9-BD79-7EF8E00FC151Q40039769-52F14E49-3474-4467-9F58-CF3AE0F9D0B1Q40043685-DF97F0A6-DC1A-466F-BD47-5E062F984466Q40056179-AFC3EBF8-E1ED-4205-B120-F51E09192A38Q40056187-29FA1D52-52D5-4315-9D16-6ECD38EF8DABQ40061368-C0B5C4DB-8C4B-42CF-ADBE-7FF03C17C698Q40070709-1CDB449D-82C5-4F5F-B9F3-DE6FD127E176Q40074385-14A7616E-29C9-4144-AE06-59177C88A8C7Q40088356-1702093A-C14C-4E0C-8CB0-727B64D75CA4Q41922286-AF580E58-5B82-45FE-B088-0392FAD7DF1CQ42373127-D85E7310-E5F7-44E3-94DB-79C6396C32ABQ47548101-FCC75FDA-AE5C-474A-B787-F4C5BDE5DD95Q47549288-1C4D3B9C-73F2-4757-B409-0964B439D581Q51784478-B6AEC26F-D592-4530-8898-D31F2D081553Q54218743-6D78F80B-7F06-4CFF-8A45-4D83B642E211Q56535662-14923F9D-BE79-4E61-B373-91C3C65F4AD2Q56536340-BB25B7F7-8C9B-4CDF-9254-01DA19F2E459Q56558172-AD45EEAD-77EA-4FE7-B5FF-D2AAAA2F49E5
P2860
Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Cross-Reactive and Potent Neut ...... Natural Ebolavirus Infection.
@ast
Cross-Reactive and Potent Neut ...... Natural Ebolavirus Infection.
@en
type
label
Cross-Reactive and Potent Neut ...... Natural Ebolavirus Infection.
@ast
Cross-Reactive and Potent Neut ...... Natural Ebolavirus Infection.
@en
prefLabel
Cross-Reactive and Potent Neut ...... Natural Ebolavirus Infection.
@ast
Cross-Reactive and Potent Neut ...... Natural Ebolavirus Infection.
@en
P2093
P2860
P50
P1433
P1476
Cross-Reactive and Potent Neut ...... Natural Ebolavirus Infection.
@en
P2093
Alexander Bukreyev
Andre Branchizio
Andrew B Ward
Benjamin J Doranz
Charles D Murin
Christopher Bryan
Curtis Klages
Edgar Davidson
Hannah King
Hannah L Turner
P2860
P304
P356
10.1016/J.CELL.2015.12.022
P407
P50
P577
2016-01-20T00:00:00Z